Find Clinical Trial

Home » Find Clinical Trials » Phase I dose-escalation study of the orally administrered selective Bcl-2 inhibitor S055746 as monotherapy for the treatment of patients with Acute Myeloid Leukaemia (AML) or high or very high risk Myelodysplastic Syndrome (MDS)

Phase I dose-escalation study of the orally administrered selective Bcl-2 inhibitor S055746 as monotherapy for the treatment of patients with Acute Myeloid Leukaemia (AML) or high or very high risk Myelodysplastic Syndrome (MDS)

← Back

Study Phase	Phase 1

Therapeutic Area	Cancers

Indication	Blood cancer

Sponsor	Institut de Recherches Internationales Servier (I.R.I.S)

Active substance/ Medical device	S055746

Active Substance Code	S055746

Protocol Code	CL1-055746-002

EudraCT Code	2014-002559-24

NCT Code	NCT02920541

ISRCTN Code	ISRCTN73586707

Documents and links

Lay summary

Results summary	READ MORE

Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.